Good
Mostly Aligned
Patient Risk:
Low
Summary
The claims largely align with the prescribing information for clobetasol propionate foam (0.05% emulsion) as provided, with most statements supported or partially supported. Several claims reference an ointment vehicle or broader inflammatory skin conditions not specific to the foam label, which introduces minor mismatches. A few explicit infection-related or site-specific exclusions present in the extracted claims are not explicitly stated in the label, representing omissions.
Category Scores
Accurate Statements
Clobetasol propionate ointment USP 0.05% is a high-potency topical corticosteroid.
supported
Clobetasol propionate ointment USP 0.05% is used to treat certain inflammatory skin conditions.
supported
It is often prescribed for short-term treatment of severe eczema/dermatitis.
partially supported
It is used for severe eczema/dermatitis when a stronger steroid is needed.
partially supported
It is often prescribed for short-term treatment of psoriasis (in selected cases).
supported
It is often prescribed for short-term treatment of other steroid-responsive inflammatory skin disorders.
supported
It is applied as a thin film to the affected area.
supported
It is typically applied once or twice daily.
partially supported
Do not use longer than prescribed; it is commonly limited to about 2 weeks for many conditions unless a clinician directs otherwise.
supported
Because it is high potency, risks increase with overuse.
supported
Do not use on the face, groin, or underarms unless specifically instructed.
supported
Do not cover with airtight dressings (e.g., plastic) unless told; can increase absorption.
supported
Long-term or excessive use can cause skin thinning (atrophy).
supported
Long-term or excessive use can cause burning/irritation.
supported
Long-term or excessive use can cause stretch marks.
supported
Long-term or excessive use can cause worsening infections.
supported
Rarely with heavy use, there can be systemic steroid effects (suppression of the adrenal gland).
supported
In pregnancy or breastfeeding, it’s usually reserved for short-term, limited-area use only.
supported
In children, higher absorption risk exists.
supported
In children, it should be used only if prescribed and generally with strict limits.
supported
Unsupported Statements
Do not use on infected areas.
Not explicitly stated in the labeling; infection management is described (treat with antimicrobial; discontinue if infection persists).
Do not use on broken skin.
Not explicitly stated in the labeling.
Contradictions
Important Omissions
Label describes foam/emulsion; some claims reference 'ointment' which is not aligned with the provided labeling.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Safety statements in the label cover HPA axis suppression potential, local adverse reactions, and infection management. Notable omissions relate to vehicle differences (ointment vs foam) and explicit broken-skin infection cautions not stated in the label.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement
Align vehicle terminology with label (foam/emulsion) and avoid extrapolating 'ointment' statements to the foam label; explicitly state whether guidance applies to foam vs other vehicles. Consider clarifying infection-related cautions to reflect label wording (discontinue if infection persists) rather than asserting absolute avoidance.